Understanding Blood Vessel Changes After Preeclampsia
This study is looking into why women who had preeclampsia (a serious blood pressure condition during pregnancy) might be at higher risk for heart problems later in life. Researchers will test how blood vessels respond to a substance called Compound 21, sometimes with L-NAME, which helps understand how blood vessels widen. They will compare women who had preeclampsia to those who had a healthy pregnancy. The goal is to find out what causes lasting damage to blood vessels and how to better manage heart disease risk in these women. You can join if you are a woman between 18 and 45 years old, and are 12 weeks to 5 years postpartum. The study will measure changes in blood flow to see if the treatments are successful.
- Study design
- This is an interventional study planning to enroll 30 women. It compares women who had preeclampsia to those who had a healthy pregnancy.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Blood flow responses will be measured at 1 hour after skin perfusion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Anna Reid-Stanhewicz, PhD · PRINCIPAL_INVESTIGATOR · University of Iowa
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in microvascular blood flow response to local compound 21 treatment measured by laser-Doppler flowmetrypost 1 hour of skin perfusion
Cutaneous vascular vasodilator response (cutaneous conductance; %max) to exogenous compound 21 perfusion; intradermal microdialysis for the local delivery of compound 21
- Change in microvascular endothelial function following local C21 treatment compared to placebo treatment measured by laser-Doppler flowmetrypost 1 hour of skin perfusion
Cutaneous vascular vasodilator response (cutaneous conductance; %max) to local heating of the skin; intradermal microdialysis for the local delivery of compound 21 compared to control (Ringer's solution), followed by L-NAME infusion to quantify NO-dependent response